BREAKING:Federal government announces new climate policy - developing story
News Rocky Ridge
Watch Live
HomehealthIncretin-Based Drugs May Reduce Risk of Dementia in Patients With Type 2 Diabetes
HEALTHBreaking News

Incretin-Based Drugs May Reduce Risk of Dementia in Patients With Type 2 Diabetes

Dipeptidyl peptidase 4 inhibitors and glucagon-like peptide 1 receptor agonists were found to offer neuroprotective effects to patients administering the medications.

image name
Pharmacy Times
Political Correspondent
Published: 1/19/2026
Updated: 1/20/2026
8 min read
image name

Pharmacy Times reports on Incretin-Based Drugs May Reduce Risk of Dementia in Patients With Type 2 Diabetes

Share this article:

Results from a population-based study published by investigators in Drug Safety demonstrate that dipeptidyl peptidase 4 (DPP-4) inhibitors and glucagon-like peptide 1 receptor agonists (GLP-1 RAs) could reduce the risk of dementia compared with sulfo...

Tags:Climate ChangeParliamentEnvironmentPoliticsEnergy Policy
image name

Pharmacy Times

Pharmacy Times is a trusted source for political news and analysis. Our correspondents provide in-depth coverage of government activities and policy developments.

@pharmacytimescontact@pharmacytimes.com

Related Articles

Comments (47)

Sort by:
Please keep comments respectful and on-topic.
image name
Mike Chen2 hours ago

Finally some real action on climate change. This legislation is long overdue and I hope it passes quickly despite the opposition from oil-dependent provinces.

image name
Jennifer Walsh3 hours ago

As someone who works in Alberta's energy sector, I'm concerned about the economic impact. The transition fund sounds good in theory but will it actually help workers like me?